Browse by Series:

CRC Safety Lead-in: ASCO GI 2019 Updates

Insights From: Scott Kopetz, MD, PhD, FACP, The University of Texas MD Anderson Cancer Center; Ryan Corcoran, MD, PhD, Massachusetts General Hospital Cancer Center
Published: Thursday, Jan 31, 2019



Scott Kopetz, MD, PhD, FACP; Ryan Corcoran, MD, PhD; review the design and updated safety lead-in data from the BEACON study looking at the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen also tested in the ANCHOR trial.
SELECTED
LANGUAGE
Slider Left
Slider Right


Scott Kopetz, MD, PhD, FACP; Ryan Corcoran, MD, PhD; review the design and updated safety lead-in data from the BEACON study looking at the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen also tested in the ANCHOR trial.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x